Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 1 | — | — |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 2 | Y005457 | — |
No additional AE; HCP called to report a 17-year-old patient received a dose of PEDVAX HIB. HCP verified patient was previously vaccinated 11/01/2007; This spontaneous report was received from a Physician Assistant and refers to a 17-year-old female patient. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were not reported. On 01-NOV-2001, the patient was vaccinated with the first dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB) (dose, route of administration, vaccination scheme frequency, anatomical site of injection, lot number and expiration date were not reported). On 04-APR-2025, when the patient was 17-years-old, she was vaccinated with a second dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), Injection 0.5 mL, (lot number Y005457 has been verified to be valid for Haemophilus b Conjugate Vaccine [Meningococcal Protein Conjugate] [LIQUID PEDVAX HIB], expiration date 06-NOV-2026; route of administration, vaccination scheme frequency and anatomical site of injection were not provided); both doses were administered as prophylaxis (Inappropriate schedule of product administration). No additional adverse event was reported for the patient.